That is seen in pancreatic cancer cells, where simultaneous targeting of Ref-1/APE1 and STAT3 signaling, using an upstream JAK2 inhibitor Ruxolitinib, synergistically inhibits proliferation and migration13 and slows growth in 3D pancreatic cancer spheroids (Fig. 3). The gene discussed is JAK2; the disease is pancreatic neoplasm.